Familial Pancreatic Ductal Adenocarcinoma

Kelly E. Diaz, Aimee L. Lucas

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage. Current screening methods are largely imaging based, but a more focused screening approach based on modifiable and nonmodifiable risk factors may improve the efficacy and likely outcomes of screening. In addition, the pathologic mechanisms that lead to the development of PDAC are discussed in an effort to further understand the targets of pancreatic cancer screening. The focus of this article will be inherited pancreatic cancer syndromes and familial pancreatic cancer, which together compose up to 10% of PDAC. Understanding the methods and targets of PDAC screening in high-risk individuals may translate to improved morbidity and mortality.

Original languageEnglish
Pages (from-to)36-43
Number of pages8
JournalAmerican Journal of Pathology
Issue number1
StatePublished - Jan 2019


Dive into the research topics of 'Familial Pancreatic Ductal Adenocarcinoma'. Together they form a unique fingerprint.

Cite this